The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden

Abstract

Purpose Advanced non-small cell lung cancer (aNSCLC) impacts the lives of patients and their caregivers. This analysis examined the association between patient clinical characteristics and patient and caregiver humanistic burden. Methods Data for patients with aNSCLC and their informal caregivers in France, Germany and Italy, were collected between May 2015 and June 2016 via chart review and patient and caregiver surveys. Patients and caregivers completed validated instruments to evaluate their health state (EuroQol-5-dimensions-3-levels [EQ-5D-3L]), work and activity impairment (Work Productivity Activity Impairment [WPAI]) and health-related quality of life (HRQoL; European Organisation for Research and treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]). Caregivers also completed the Zarit Burden Interview (ZBI). Univariate and regression analyses were stratified by patient Eastern Cooperative Group Performance Status (ECOG-PS 0, 1, 2 or 3/4). Results In total, 1030 patients and 427 accompanying informal caregivers participated. Regression analyses indicated that patients reported lower EQ-5D-3L utility index, EQ-VAS and EORTC QLQ-C30 global health status and greater work and activity impairment with worsening ECOG-PS (all p < 0.05). Caregivers also reported greater activity impairment and higher ZBI scores with worsening ECOG-PS of the patient they were providing care for (all p < 0.05). Conclusions As patients’ functionality deteriorates as measured by the ECOG-PS, so do their outcomes related to health utility, work productivity, activity impairment and HRQoL. This deterioration is also reflected in increased caregiver burden and activity impairment. There is a need for interventions to maintain patients’ physical function to relieve the humanistic burden of both patients and caregivers. Electronic supplementary material The online version of this article (10.1007/s11136-019-02152-6) contains supplementary material, which is available to authorized users.

Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer

“…The remaining 24 studies were excluded from subsequent analyses [ 59 – 82 ]. Among the excluded studies, four did not measure HRQoL in patients [ 72 , 77 , 81 , 82 ], nine did not use valuation by members of the general public [ 59 , 60 , 63 , 69 , 71 , 72 , 74 , 81 , 82 ], 11 did not use a choice-based method for valuation [ 59 , 63 , 65 , 67 – 71 , 74 , 76 , 81 ], and nine had missing data on one or more of these items [ 61 , 62 , 64 , 66 , 73 , 75 , 78 – 80 ].…”

Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort

“…Our study found that patients in MDEs had an average utility value of 0.41, and this value was higher for patients in improved health states. In two real-world studies, a utility value was estimated at 0.80 in 505 French patients with untreated chronic hepatitis C and at 0.67 in 1030 European patients with advanced non-small cell lung cancer [ 39 , 40 ]. Ara et al [ 41 ] found that the average utility value for patients with mental illness, depression, or neurosis was 0.61.…”

Dimensionality and Measurement Invariance of the Italian Version of the EORTC QLQ-C30 in Postoperative Lung Cancer Patients

“…In fact, only four studies measured QoL in Italian lung cancer patients through the administration of the EORTC QLQ-C30. Two of them were international studies and involved several countries, with all of them focusing on non-small cell lung cancer (Di Maio et al, 2004; Maione et al, 2005; Koller et al, 2017; Wood et al, 2019).…”